(Total Views: 608)
Posted On: 02/04/2021 6:36:48 PM
Post# of 148908
My god, I knew I was near clueless, but I had no idea I was completely clueless
If Leronlimab suppresses PDL1 expression by cancer cells, thats nearly the same as Opdivo, except Opdivo hits the receptor and LL kills the pathway at the source inside the tumor cell.
Opdivo is running $7 billion annually.
Pourhassan can't possibly know this. He would be calling for quadruple digits.
Probably the maraviroc in the experiment did not suppress PDL1 expression as well as Opdivo blocks the receptor, but I will endeavor to find out
In my previous post I was going to suggest Bristol Meyers Squibb as a potential buyer for Cytodyn, but if LL is knocking out PDL1 expression in cancer cells, then Cytodyn is a mortal threat to the $7 billion per year Bristol Meyers Squibb Opdivo franchise.
However, probably even if LL proves very effective at suppressing PDL1 expression in cancer cells, then LL and Opdivo will be used at the same time in all of the patients.
Opdivo blocks the receptor and LL blocks production of the ligand that binds the receptor.
LOL I still don't know the exact function of Opdivo, but I think it probably binds the receptor.
Blockade of PDL1 expression in cancer cells is an MOA totally different than chemotaxis and macrophage repolarization.
Am I the only dummy who has never heard of this Leronlimab MOA for cancer?????
If Leronlimab suppresses PDL1 expression by cancer cells, thats nearly the same as Opdivo, except Opdivo hits the receptor and LL kills the pathway at the source inside the tumor cell.
Opdivo is running $7 billion annually.
Pourhassan can't possibly know this. He would be calling for quadruple digits.
Probably the maraviroc in the experiment did not suppress PDL1 expression as well as Opdivo blocks the receptor, but I will endeavor to find out
In my previous post I was going to suggest Bristol Meyers Squibb as a potential buyer for Cytodyn, but if LL is knocking out PDL1 expression in cancer cells, then Cytodyn is a mortal threat to the $7 billion per year Bristol Meyers Squibb Opdivo franchise.
However, probably even if LL proves very effective at suppressing PDL1 expression in cancer cells, then LL and Opdivo will be used at the same time in all of the patients.
Opdivo blocks the receptor and LL blocks production of the ligand that binds the receptor.
LOL I still don't know the exact function of Opdivo, but I think it probably binds the receptor.
Blockade of PDL1 expression in cancer cells is an MOA totally different than chemotaxis and macrophage repolarization.
Am I the only dummy who has never heard of this Leronlimab MOA for cancer?????
(4)
(0)Scroll down for more posts ▼
